FDA Calendar

Company Name La Jolla Pharmaceutical Co
Drug Name LJPC-501 (angiotensin II) (NDA)
Event Name FDA decion on LJPC-501 or the treatment of hypotension in adults with distributive or vasodilatory shock
Event Date 02/28/2018
Outcome Date 12/21/2017
Outcome FDA approved Giapreza, formerly known as LJPC-501, on Dec.21, 2017
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
Return to FDA Calendar